Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis: A Nationwide 20-Year Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis : A Nationwide 20-Year Cohort Study. / Egeberg, Alexander; Thyssen, Jacob P; Burisch, Johan; Colombel, Jean-Frederic.

In: The Journal of Investigative Dermatology, Vol. 139, No. 2, 2019, p. 316-323.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Egeberg, A, Thyssen, JP, Burisch, J & Colombel, J-F 2019, 'Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis: A Nationwide 20-Year Cohort Study', The Journal of Investigative Dermatology, vol. 139, no. 2, pp. 316-323. https://doi.org/10.1016/j.jid.2018.07.029

APA

Egeberg, A., Thyssen, J. P., Burisch, J., & Colombel, J-F. (2019). Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis: A Nationwide 20-Year Cohort Study. The Journal of Investigative Dermatology, 139(2), 316-323. https://doi.org/10.1016/j.jid.2018.07.029

Vancouver

Egeberg A, Thyssen JP, Burisch J, Colombel J-F. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis: A Nationwide 20-Year Cohort Study. The Journal of Investigative Dermatology. 2019;139(2):316-323. https://doi.org/10.1016/j.jid.2018.07.029

Author

Egeberg, Alexander ; Thyssen, Jacob P ; Burisch, Johan ; Colombel, Jean-Frederic. / Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis : A Nationwide 20-Year Cohort Study. In: The Journal of Investigative Dermatology. 2019 ; Vol. 139, No. 2. pp. 316-323.

Bibtex

@article{ea48003bd2784a57b7b4592c88d4c011,
title = "Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis: A Nationwide 20-Year Cohort Study",
abstract = "In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and certain clinical trials, yet the association remains poorly understood. We studied a 20-year nationwide cohort of 235,038 Danish adults with psoriasis and a 1:1 matched reference group. Less than 1{\%} of psoriasis patients developed CD or UC during follow-up. Incidence rates of CD were highest for younger women with psoriasis and patients with concurrent psoriatic arthritis, whereas men with psoriasis had particularly high incidence rates of UC compared with their non-psoriasis peers. Adjusted hazard ratios of CD were 1.84 (95{\%} confidence interval [CI]= 1.47-2.29) and 2.38 (95{\%} CI = 1.62-3.49) among psoriasis patients treated with topical and systemic nonbiologic therapy, respectively. No definite CD cases occurred during biologic therapy. For UC, adjusted hazard ratios were 1.49 (95{\%} CI = 1.29-1.72), 1.51 (95{\%} CI = 1.14-2.01), and 1.23 (95{\%} CI = 0.39-3.86, P = 0.7197) for psoriasis patients receiving topical, systemic nonbiologic, and biologic therapy, respectively. Time to CD (but not UC) diagnosis was significantly longer for psoriasis patients compared with the general population, and patients receiving systemic treatment had the longest time to CD and UC. Psoriasis was associated with increased risk of CD and UC. Particular risk factors included sex and psoriatic arthritis.",
author = "Alexander Egeberg and Thyssen, {Jacob P} and Johan Burisch and Jean-Frederic Colombel",
note = "Copyright {\circledC} 2018 The Authors. Published by Elsevier Inc. All rights reserved.",
year = "2019",
doi = "10.1016/j.jid.2018.07.029",
language = "English",
volume = "139",
pages = "316--323",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "nature publishing group",
number = "2",

}

RIS

TY - JOUR

T1 - Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis

T2 - A Nationwide 20-Year Cohort Study

AU - Egeberg, Alexander

AU - Thyssen, Jacob P

AU - Burisch, Johan

AU - Colombel, Jean-Frederic

N1 - Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

PY - 2019

Y1 - 2019

N2 - In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and certain clinical trials, yet the association remains poorly understood. We studied a 20-year nationwide cohort of 235,038 Danish adults with psoriasis and a 1:1 matched reference group. Less than 1% of psoriasis patients developed CD or UC during follow-up. Incidence rates of CD were highest for younger women with psoriasis and patients with concurrent psoriatic arthritis, whereas men with psoriasis had particularly high incidence rates of UC compared with their non-psoriasis peers. Adjusted hazard ratios of CD were 1.84 (95% confidence interval [CI]= 1.47-2.29) and 2.38 (95% CI = 1.62-3.49) among psoriasis patients treated with topical and systemic nonbiologic therapy, respectively. No definite CD cases occurred during biologic therapy. For UC, adjusted hazard ratios were 1.49 (95% CI = 1.29-1.72), 1.51 (95% CI = 1.14-2.01), and 1.23 (95% CI = 0.39-3.86, P = 0.7197) for psoriasis patients receiving topical, systemic nonbiologic, and biologic therapy, respectively. Time to CD (but not UC) diagnosis was significantly longer for psoriasis patients compared with the general population, and patients receiving systemic treatment had the longest time to CD and UC. Psoriasis was associated with increased risk of CD and UC. Particular risk factors included sex and psoriatic arthritis.

AB - In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and certain clinical trials, yet the association remains poorly understood. We studied a 20-year nationwide cohort of 235,038 Danish adults with psoriasis and a 1:1 matched reference group. Less than 1% of psoriasis patients developed CD or UC during follow-up. Incidence rates of CD were highest for younger women with psoriasis and patients with concurrent psoriatic arthritis, whereas men with psoriasis had particularly high incidence rates of UC compared with their non-psoriasis peers. Adjusted hazard ratios of CD were 1.84 (95% confidence interval [CI]= 1.47-2.29) and 2.38 (95% CI = 1.62-3.49) among psoriasis patients treated with topical and systemic nonbiologic therapy, respectively. No definite CD cases occurred during biologic therapy. For UC, adjusted hazard ratios were 1.49 (95% CI = 1.29-1.72), 1.51 (95% CI = 1.14-2.01), and 1.23 (95% CI = 0.39-3.86, P = 0.7197) for psoriasis patients receiving topical, systemic nonbiologic, and biologic therapy, respectively. Time to CD (but not UC) diagnosis was significantly longer for psoriasis patients compared with the general population, and patients receiving systemic treatment had the longest time to CD and UC. Psoriasis was associated with increased risk of CD and UC. Particular risk factors included sex and psoriatic arthritis.

U2 - 10.1016/j.jid.2018.07.029

DO - 10.1016/j.jid.2018.07.029

M3 - Journal article

C2 - 30130618

VL - 139

SP - 316

EP - 323

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 2

ER -

ID: 228977622